As GenomeWeb News reported, Harvard Bio, which last week put its capital instrument business on the block, this morning said receipts for the three months ended June 30 fell to $21.7 million from $22.5 million year over year.
The firm's apparatus and instrumentation unit, which it is retaining, brought in revenue of $16.3 million for the quarter, up 4.2 percent year over year from $15.6 million. Revenue for the capital equipment segment dropped a sharp 20.3 percent to $5.4 million from $6.8 million in last year's second quarter.
Harvard Bio posted a net loss of $27.4 million, or $.90 per share, compared with a net profit of $298,000, or $.01 per share, year over year. The loss includes asset abandonment and impairment charges of $17.9 million related to the divestiture of the capital equipment business.
The firm also disclosed that it has hired investment banking firm Thomas Weisel Partners to help it find a buyer for the capital equipment segment, which includes the Genomic Solutions business. The company said it would use proceeds from the sale to pay down its $15.2 million debt facility and finance tuck-in acquisitions.
As of June 30, Harvard Bio had cash and cash equivalents of $13.2 million.